St. John's Wort:Clinical Status in Psychiatry

CNS Spectrums

Volumn 6, Issue 10, 2001, Pages 835-840

  Meltzer Brody, Samantha E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUOXETINE; HERBACEOUS AGENT; HYPERICIN; IMIPRAMINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANIMAL MODEL; ANXIETY NEUROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG OVERDOSE; DRUG SAFETY; HERBAL MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERICUM PERFORATUM; MANIA; MENTAL DISEASE; META ANALYSIS; MULTICENTER STUDY; NEUROPHARMACOLOGY; NONHUMAN; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 0035662798     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900001656     Document Type: Article

References (52)

1. Eisenberg, DM, Kessler, RC, Foster, C, et-al. Unconventional medicine in the United States. N Engl J Med. 1993; 328: 246–252.
2. Ernst, E, Rand, JI, Stevinson, C. Complementary therapies for depression. Arch Gen Psychiatry. 1998; 55: 1026–1032.
3. Astin, JA. Why patients use alternative medicine: results of a national study. JAMA. 1998; 279: 1548–1553.
4. Eisenberg, DM, Davis, RB, Ettner, SL, et-al. Trends in alternative medicine use in the United States, 1990-1997. JAMA. 1998; 280: 1569–1575.
5. Kessler, RC, Soukup, J, Davis, RB, et-al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Arch Gen Psychiatry. 2001; 158: 289–294.
6. Upton, R. St. John's Wort (Hypericum perforatum) American Herbal Pharmacopia. Santa Cruz, CA: American Herbal Pharmacopia (published in herbalgram 40), 1999; 1–32.
7. Blumenthal, M, Busse, WR, Goldberg, A, et al, eds. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston, Mass: Integrative Medicine Communications; 1998.
8. Physicians Desk Reference for Herbal Medicines, 2nd ed. Montvale, NJ: Medical Economics Company; 2000.
9. National Center for Complementary and Alternative Medicine. St. John's Wort fact sheet (publication Z-02). National Institutes of Health, Bethesda, Md; 1999.
10. Greeson, JM, Sanford, B, Monti, DA. St. John's wort (hypericum perforatum): a review of the current pharmacological, toxicological and clinical literature. Psychopharmacology (Berl). 2001; 153: 402–414.
11. Gaster, B, Holroyd, J. St. John's wort for depression: a systematic review. Arch Intern Med. 2000; 160: 152–156.
12. Wagner, H, Bladt, S. Pharmaceutical quality of Hypericum extracts. J Geriatr Psychiatry Neurol. 1994; 7(suppl 1) S65–68.
13. Nangia, M, Syed, W, Doraiswamy, PM. Efficacy and safety of St. John's wort for the treatment of major depression. Public Health Nutr. 2000; 3: 487–494.
14. Suzuki, O, Katsumata, Y, Oya, M, et-al. Inhibition of monoamine oxidase by hypericin. Planta Medicine. 1984; 50: 272–274.
15. Cott, JM. In vitro receptor binding and enzyme inhibition by hypericum perforatum extract. Pharmacopsychiatry (Berl). 1997; 30(suppl 2):108–112.
16. Chatterjee, SS, Noldner, M, Kode, E, et-al. Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry (Berl). 1998; 31(suppl 1):7–15.
17. Singer, A, Wonnemann, M, Miller, WE. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+. J Pharmacol Exp Therapy. 1999; 290: 1363–1368.
18. Kaehler, ST, Sinner, C, Chatterjee, SS, Philippu, A. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rate locus ceruleus. Neurosci Lett. 1999; 262: 199–202.
19. Laakmann, G, Schule, C, Baghai, T, Kieser, M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry (Berl). 1998; 31: 54–59
20. Thiede, HM, Walper, A. Hypericin inhibition of MAO and COMT by hypericum extracts and hypercin. J Geriatr Psychiatry Neurol. 1994; 7(suppl 1):S54–56.
21. Bladt, S, Wagner, H. Inhibition of MAO by fractions and constituents of Hypericum extract. J Geriatr Psychiatry Neurol. 1994; 7(suppl 1):S57–59.
22. Cott, J. Medical plants and dietary supplements: sources for innovative treatments or adjuncts? Psychopharmacol Bull. 1995; 31: 131–137.
23. Muller, WE, Rolli, M, Schafer, C, Hafner, U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 1997; 30(suppl 2):102–107.
24. Rolli, M, Schafer, C, Muller, WE. Effect of hypericum extract (LI 160) on neurotransmitter receptor binding and synaptosomal uptake systems. Pharmacopsychiatry (Berl). 1995; 28: 207.
25. Neary, JT, Bu, Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res. 1999; 816: 358–363.
26. Schrader, E, on behalf of the Study Group. Equivalence of St. John's wort extract and fluoxetine: a randomized controlled study in mild-moderate depression. Int Clin Psychopharmacol. 2000; 15: 61–68.
27. Baureithel, KH, Butner, KB, Engesser, A, Bukard, W, Schaffer, W. Inhibition of benzodiazepine in vitro by amentoflavone, a constituent of various species of hypericum. Pharm Acta Helv. 1997; 72: 153–157.
28. Thiele, B, Brink, I, Ploch, M. Modulation of cytokine expression by Hypericum extract. J Geriatr Psychiatry Neurol. 1994; 7(suppl l):S60–62.
29. Miller, AL. St. John's wort (Hypericum perforatum); Clinical effects on depression and other conditions. Altern Med Rev. 1998; 33: 18–26.
30. Franklin, M, McGavin, C, Reed, A, Cowen, PJ. Effect of hypericum perforatum on salivary cortisol in health male volunteers. J Psychopharmacology. 1998; 30: A16.
31. Raffa, RB. Screen of receptor and uptake-site activity of hypericin components of St. John's wort reveals sigma receptor binding. Life Sci. 1998; 62: 265–270.
32. Linde, K, Ramirez, G, Mulrow, CD, Pauls, A, Weidenhammer, W, Melchart, D. St. John's wort for depression—overview and meta-analysis of randomized clinical trials. BMJ. 1996; 313: 253–258.
33. Shelton, RC, Keller, MB, Gelenberg, A, et-al. Effectiveness of St. John's wort in major depression: a randomized controlled trial. JAMA. 2001; 285: 1978–1986.
34. Linde, K, Mulrow, CD. St. John's wort for depression. The Cochrane Database of Systematic Reviews. The Cochrane Library, The Cochrane Collaboration, 1999, vol4.
35. Kim, HL, Streltzer, J, Goebert, D. St. John's wort for depression: A meta analysis of well-defined clinical trials. J Nerv Ment Dis. 1999; 187: 532–538.
36. Volz, HP, Laux, P. Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine. Compr Psychiatry. 2000; 41(suppl 1):133–137.
37. Woelk, H. Comparison of St. John's wort and imipramine for treating depression: randomized controlled trial. BMJ. 2000; 321: 536–539.
38. Wheatley, D. LI 160, an extract of St. John's wort versus amitriptyline in mildly to moderately depressed outpatients—a controlled 6-week clinical trial. Pharmacopsychiatry (Berl). 1997; 30(suppl 2):77–80.
39. Montgomery, SA, Hubner, WD, Grigoleit, HG. Efficacy and tolerability of St. John's wort extract compared to placebo in patients with a mild to moderate depressive disorder. Phytomedicine. 2000; 7: 107.
40. Vorbach, EU, Arnoldt, KH, Hubner, WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry (Berl). 1997; 30(suppl 2):81–5.
41. Taylor, LVH, Kobak, KA. An open-label trial of St. John's wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry. 2000; 61: 575–578.
42. Davidson, JRT, Connor, KM. St. John's wort in generalized anxiety disorder: three case reports. J Clin Psychopharmacology. In press.
43. Grube, B, Walper, A, Wheatley, D. St. John's wort extract: efficacy for menopausal symptoms of psychological origin. Adv Ther. 1999; 16: 177–186.
44. Rezvani, AH, Overstreet, DH, Yang, Y, Clark, E. Attenuation of alcohol intake by extract of hypericum perforatum (St. John's wort) in two different strains of alcohol-preferring rats. Alcohol Alcohol. 1999; 34: 699–705.
45. Woelk, H, Burkard, G, Grunwald, J. Benefits and risks of the hypericum extract LI 160: drug monitoring study with 3250 patients. J Geriatr Psychiatry Neurol. 1994; 7(suppl 1):S34–S38.
46. Brockmoller, J, Reum, T, Bauer, S, Kerb, R, Hubner, WD, Roots, I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry. 1997; 30(suppl 2):94–101.
47. Bove, GM. Acute neuropathy after exposure to sun in a patient treated with St. John's wort. Lancet. 1998; 352: 1121–1122.
48. Gulick, RM, McAuliffe, V, Holden-Wiltse, J, et-al. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med. 1999; 130: 510–514.
49. Czekalla, J, Gastpar, M, Hubner, WD, Jager, D. The effect of hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry (Berl). 1997; 30(suppl 2):86–88.
50. Nierenberg, A, Burt, T, Matthews, J, Weiss, A. Mania associated with St. John's wort. Biol Psychiatry. 1999; 46: 1707–1708.
51. Moses, EL, Mallinger, AG. St. John's wort: Three cases of possible manic induction. J Clin Psychopharmacol. 2000; 20: 115–117.
52. Davidson, JRT, Connor, KM. Herbs for the Mind: What Science Tells Us About Nature's Remedies for Depression, Stress, Memory Loss and Insomnia. New York, NY: Guilford Publications; 2000.